Hansa Medical in brief

Hansa Medical is a biopharmaceutical company developing novel immunomodulatory enzymes for transplantation and acute autoimmune diseases. The lead project imlifidase is a proprietary antibody-degrading enzyme currently in late-stage clinical development for kidney transplant patients, with significant potential for further development in other solid organ transplants and a wide range of acute autoimmune indications. The company also has a strong pipeline of preclinical assets that may provide a second wave of potential drugs. Under the project name NiceR, novel immunoglobulin cleaving enzymes are developed for repeat dosing translating the Hansa Medical technology into relapsing autoimmune diseases and potentially oncology. Hansa Medical is based in Lund, Sweden, its shares (ticker: HMED) are listed on Nasdaq Stockholm.

Key facts

  • Innovative and promising pipeline
    • Imlifidase – candidate drug in several Phase II trials in kidney transplantation
    • NiceR - Novel immunoglobulin cleaving enzymes for Repeat dosing
    • EnzE - Enzyme based antibody Enhancement
    • HBP-assay – diagnostic assay to predict severe sepsis (licensed to Axis-Shield Diagnostics)
  • First-rate global scientific network within transplantation and immunology
  • Board of Directors with long pharma and biotech experience
  • Small and innovative team (Approx. 40 employees)
  • Based in Lund, Sweden
  • Listed on NASDAQ Stockholm (ticker: HMED)
  • 534 MSEK in cash and short term investments, June 30, 2018